As Amgen approached an FDA decision last month for its migraine-prevention treatment, concern mounted that the drug would come at premium. In setting a price thousands of dollars less than expected, Amgen has won over one of the pharmaceutical industry’s fiercest drug price critics.
The non-profit Institute for Clinical and Economic Review (ICER) assessed the effectiveness and value of the Amgen (NASDAQ: AMGN) drug erenumab (Aimovig) and other new migraine drugs, and concluded in an updated report that erenumab offers value to patients in the price range of $3,700 to $5,300 per year. After the FDA approved erenumab last… Read more »
UNDERWRITERS AND PARTNERS